David DeWahl

David DeWahl is a highly accomplished executive with extensive experience in the healthcare industry. He holds an MBA from Columbia University as well as a Bachelor of Arts in Economics from the University of Wisconsin-Madison. David currently serves as the President and CEO of Ischemix, Inc., a biotechnology company focused on developing treatments for stroke and other neurological conditions. Prior to this, he held various executive positions at Colchester Healthcare Investments, Helix Therapeutics, Life Science Group, Vector Securities, and Prudential Securities. David brings a wealth of knowledge and expertise to his current role, where he leads his team in continuing to push the boundaries of biotechnology research and development.